Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass
Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines are pleased to announce the DMT Conference.
The two-day virtual conference is to take place on September 9-10th 2021, starting at 12 pm EDT.
Join us as we take a scientific deep dive into the dynamic field of DMT therapeutics, with expert panels and engaging discussions.
Our Molecular Masterclasses are a speaker series designed for deep dives into the world's favourite psychoactive and psychedelic substances. Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world. This year's DMT Masterclass will feature content around:
Science & Research
Drug Development & Safety
Clinical Applications
Law & Regulation
Business & Markets
History & Culture
Confirmed speakers include: Timothy Ko, Christopher Moreau, Dr. Carol Routledge, Dr. Joseph Tucker, David Wood, Ruth Chun, Hadas Alterman, Rick Strassman, Brian Jahns, Crystal Carson, Joel Brierre.
If you are interested in speaking at The DMT Conference, please apply by completing our online submission form.
Check out previous Masterclasses: Ketamine Masterclass, Ibogaine Masterclass, Mushroom Conference, MDMA Masterclass.
If you are interested in learning about sponsorship opportunities for The DMT Conference, reach out to kristina@microdose.buzz for details.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91235
DISCLAIMER:
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDARplus.ca for important risk disclosures. It’s your money and your responsibility.